This is a major de-risking event for ARTV. The 71% ACR50 response rate in a highly refractory RA population and FDA alignment on a single Phase 3 trial design significantly reduce clinical and regulatory risk. The ATM suspension removes a dilution overhang. Watch for EULAR 2026 presentations (late-breaking oral) and Phase 3 trial initiation in H2 2026 as the next catalysts. The stock should re-rate on the improved probability of success.
Price Chart
Executive Summary
Artiva reported Q1 2026 net loss of $23.5M ($0.95/share), slightly wider than the $20.3M loss a year ago, with cash burn reducing the balance to $86.8M (funding into Q2 2027). The headline event is the positive initial Phase 2a clinical data for AlloNK in refractory RA (71% ACR50 at 6 months) and FDA alignment on a single Phase 3 registrational trial design, representing a major de-risking catalyst for a pre-revenue biotech. The company also suspended its ATM facility, removing near-term dilution overhang.
Key Financial Metrics
Key Facts
- Net loss of $23.5M for Q1 2026 vs $20.3M in Q1 2025; net loss per share $0.95 vs $0.83
- Cash, cash equivalents and investments of $86.8M as of March 31, 2026, expected to fund operations into Q2 2027
- 71% ACR50 response rate in 7 refractory RA patients with 6 months follow-up in company-sponsored Phase 2a basket trial
- FDA alignment on a single Phase 3 registrational RCT in ~150 refractory RA patients; trial initiation planned for H2 2026
- No CRS, ICANS, or treatment discontinuations related to AlloNK reported; Grade 3+ infection rate of 2%
- ATM facility suspended; no further sales of common stock under existing prospectus supplement
- More than 70 autoimmune patients treated with AlloNK across 40+ active clinical sites globally
Financial Impact
Pre-revenue clinical-stage biotech; cash burn of ~$23.5M/quarter; $86.8M cash runway into Q2 2027
Risk Factors
- Phase 3 trial may fail to replicate Phase 2a results in a larger, randomized setting
- Official FDA minutes may contain interpretations differing from company's understanding
- Cash runway only into Q2 2027; may need additional financing before Phase 3 data readout in H2 2028
- Competition from auto-CAR-T, T-cell engagers, and other deep B-cell depleting therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-213239 |
| Document: d38160d8k.htm | 0001193125-26-213239 |
| Document: d38160dex993.htm | 0001193125-26-213239 |
| Document: d38160dex992.htm | 0001193125-26-213239 |
| Document: 0001193125-26-213239-index-headers.html | 0001193125-26-213239 |
| Document: 0001193125-26-213239-index.html | 0001193125-26-213239 |
| Document: 0001193125-26-213239.txt | 0001193125-26-213239 |
| 8-K Data (Synthetic) | 0001193125-26-213239 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access